Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;39(8):4043-4053.
doi: 10.21873/anticanres.13560.

The Anticancer and Antioxidant Effects of Muscadine Grape Extracts on Racially Different Triple-negative Breast Cancer Cells

Affiliations

The Anticancer and Antioxidant Effects of Muscadine Grape Extracts on Racially Different Triple-negative Breast Cancer Cells

Patricia Mendonca et al. Anticancer Res. 2019 Aug.

Abstract

Background/aim: Triple-negative breast cancer (TNBC) is the most aggressive subtype, predominant in African American women. In this study, the antioxidant/anticancer activity of muscadine grape extracts and the role of their phenolic and flavonoid contents in exerting these properties were investigated in TNBC cells.

Materials and methods: Berry extracts from muscadine genotypes were investigated for total phenolic content (TPC), total flavonoid content (TFC), antioxidant capacity, and anticancer effects using breast cancer cell lines, representing Caucasians and African Americans.

Results: The antioxidant activity was associated with high TPC content. Extracts showed cytotoxicity up to 78.6% in Caucasians and 90.7% in African American cells, with an association with high antioxidant capacity. There was a strong correlation between TPC and anticancer/antioxidant activities.

Conclusion: The anticancer and antioxidant effects of muscadine grapes are attributed to the TPC of extracts, which showed a stronger positive correlation with growth inhibition of African American breast cancer cells compared to Caucasians.

Keywords: MDA-MB-231; MDA-MB-468; TNBC; anticancer; antioxidant; flavonoids; phenolic.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The Authors declare that there is no conflict of interest regarding the publication of this paper.

Figures

Figure 1.
Figure 1.
Illustration showing the correlation of MM-231/MM-468 cell growth inhibition versus TPC (A, B), TFC (C, D) and DPPH inhibition (E, F). Each point represents the genotype value for each of the two traits. Statistically significant differences represented by probability levels at *p<0.05, **p<0.01, and ***p<0.001 are calculated [n=196, r0.05=0.140, r0.01=0.184, r0.001=0.233].
Figure 2.
Figure 2.
PCA scatter plots of different traits. TPC: Total phenolic content; TFC: total flavonoid content; DPPH: antioxidant effect; MM-231 (Caucasian breast-cancer cells) and MM-468 (African American breast-cancer cells) anticancer activity. According to the PCA model, 53.16% and 18.55% of the variance were explained by the PC1 (TPC) and the PC2 (TFC) principal components, respectively.
Figure 3.
Figure 3.
Hierarchical clustering of phytochemical content and biological activities of muscadine population (196 genotypes). Data related to TPC, TFC, antioxidant activity, and anticancer activity for Caucasian (MM-231) and African American (MM-468) breast-cancer cells are presented as a percentage. The log2-transformed values of each character are represented by colors. Green boxes indicate higher levels and red boxes indicate lower levels compared to the control. The color change is proportional to the accumulation/activity levels.
Figure 4.
Figure 4.
Frequency distribution of berry metabolomic traits and consequent biological activities of the muscadine population (n=196). Population means of each trait are indicated.

Similar articles

Cited by

References

    1. Institute, N.C. Cancer Stat Facts: Female Breast Cancer. 2018. Available from https://seer.cancer.gov/statfacts/html/breast.html.
    1. Danforth DN Jr: Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship between biological and nonbiological factors. Breast Cancer Res 15(3): 208, 2013. DOI: 10.1186/bcr3429 - DOI - PMC - PubMed
    1. Anders CK and Carey LA: Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9: S73–S81, 2009. DOI: 10.3816/CBC.2009.s.008 - DOI - PMC - PubMed
    1. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS and Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. 295(21): 2492–4502, 2006. DOI: 10.1001/jama.295.21.2492 - DOI - PubMed
    1. Yao H, He G, Yan S, Chen C, Song L, Rosol T and Deng X: Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 8(1): 1913–1924, 2017. DOI: 10.18632/oncotarget.12284 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources